GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (OTCPK:NXSCF) » Definitions » Cash And Cash Equivalents

Next Science (Next Science) Cash And Cash Equivalents : $9.24 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Cash And Cash Equivalents?

Next Science's quarterly cash and cash equivalents declined from Dec. 2022 ($5.07 Mil) to Jun. 2023 ($3.48 Mil) but then increased from Jun. 2023 ($3.48 Mil) to Dec. 2023 ($9.24 Mil).

Next Science's annual cash and cash equivalents declined from Dec. 2021 ($7.00 Mil) to Dec. 2022 ($5.07 Mil) but then increased from Dec. 2022 ($5.07 Mil) to Dec. 2023 ($9.24 Mil).

Next Science Cash And Cash Equivalents Historical Data

The historical data trend for Next Science's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Cash And Cash Equivalents Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial 16.91 8.10 7.00 5.07 9.24

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 11.03 5.07 3.48 9.24

Next Science Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Next Science  (OTCPK:NXSCF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Next Science Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Next Science's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (Next Science) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (OTCPK:NXSCF) » Definitions » Cash And Cash Equivalents
Comparable Companies
ASX:CAN ASX:LGP ASX:ANP ASX:LV1 ASX:IVX ASX:EOF ASX:MVP ASX:ECS ASX:PXS ASX:IDT ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
NXS:Australia
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Website
https://www.nextscience.com
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.